Related Experiment Video
Updated: Jul 12, 2025
11:22
Vibratome Sectioning Mouse Retina to Prepare Photoreceptor Cultures
Published on: December 22, 2014
17.8K
Retinal Dystrophy Associated With RLBP1 Retinitis Pigmentosa: A Five-Year Prospective Natural History Study
Marie Burstedt1, James H Whelan2, Jane S Green2
1Clinical Sciences/Ophthalmology, University of Umeå, Umeå, Sweden.
Investigative Ophthalmology & Visual Science
|October 26, 2023
Summary
This five-year study of RLBP1 gene mutation patients found no significant longitudinal changes in vision or eye structure. Severely delayed dark-adaptation recovery was consistent across all participants, suggesting its potential for gene therapy trials.
Area of Science:
- Ophthalmology
- Genetics
- Retinal Diseases
Background:
- Retinal dystrophy associated with RLBP1 gene mutations is a rare inherited condition.
- Understanding the natural history of this disease is crucial for developing effective treatments.
Purpose of the Study:
- To evaluate the five-year progression of functional and structural measures in patients with RLBP1-associated retinal dystrophy.
- To establish the natural history of this rare genetic eye disease.
Main Methods:
- Prospective, noninterventional study of 45 patients with biallelic RLBP1 mutations across two international sites.
- Comprehensive assessments included ocular exams, visual function tests (BCVA, CS, DA kinetics, HVF, ERG), and structural imaging.
- High test-retest repeatability was confirmed for all measured endpoints.
Main Results:
- No significant longitudinal changes in functional or structural measures were observed over the five-year follow-up period.
- All patients exhibited severely prolonged dark-adaptation (DA) rod recovery (approx. 6 hours).
- Cross-sectional analysis showed poorer visual acuity (VA) and declining Humphrey visual field (HVF) mean depth (MD) with increasing age.
Conclusions:
- The study provides the first five-year natural history data for RLBP1-associated retinal dystrophy.
- Severely delayed DA sensitivity recovery is a consistent characteristic across all age groups, indicating its potential as a reliable endpoint for gene therapy efficacy studies.
- This finding is critical for future clinical trial design in RLBP1-related eye disease.
